Table 3.
Tumour and kidney uptake of various radiolabelled PSMA-binding ligands after 1, 4 and 24 h. N/A, not available.
| Radioligand | Mouse Strain (Cell Line) |
Tumour Uptake (%ID/G) | Kidney Uptake (%ID/G) | Reference | ||||
|---|---|---|---|---|---|---|---|---|
| 1h | 4h | 24h | 1h | 4h | 24h | |||
| 212Pb-NG001 | Hsd: athymic nude-Foxn1nu (C4-2) | 23.3 ± 8.7 | 13.6 ± 2.1 | 11.3 ± 3.4 | 62.1 ± 7.0 | 9.6 ± 2.5 | 5.2 ± 0.8 | Current study |
| 203Pb-CA012 | BALB/c nu/nu (C4-2) | 8.4 ± 3.7 | 7.8 ± 0.9 | 3.3 ± 1.6 | 5.1 ± 2.5 | 1.6 ± 0.3 | 0.9 ± 0.1 | Dos Santos et al., 2019 [5] |
| 203Pb-L2 | NOD-SCID gamma (PC-3 PIP) | 22.5 ± 8.1 | 11.6 ± 4.2 | 8.5 ± 2.1 | 23.0 ± 11.9 | 3.8 ± 1.0 | 3.1 ± 0.8 | Banerjee et al., 2020 [24] |
| 177Lu-PSMA-617 | NOD-SCID gamma (LNCaP) | 15.1 ± 5.6 | 14.5 ± 1.8 | 10.9 ± 3.3 | 97.2 ± 19.4 | 26.6 ± 19.1 | 0.6 ± 0.2 | Kuo et al., 2018 [30] |
| 177Lu-PSMA-617 | BALB/c nu/nu (LNCaP) | 11.2 ± 4.2 | N/A | 10.6 ± 4.5 | 137.2 ± 77.8 | N/A | 2.1 ± 1.4 | Benesova et al., 2015 [31] |
| 177Lu-PSMA-617 | BALB/c nu/nu (LNCaP) | N/A | 14.4 ± 1.1 | 4.6 ± 0.6 | N/A | 14.1 ± 3.1 | 0.7 ± 0.1 | Kelly et al., 2018 [32] |
| 177Lu-PSMA-617 | Athymic nude BALB/c (PC-3 PIP) | 44.2 ± 12.0 | 56.0 ± 8.0 | 37.3 ± 5.8 | 9.8 ± 1.4 | 3.4 ± 3.2 | 0.8 ± 0.9 | Benesova et al., 2018 [33] |